Eli Lilly and Company (NYSE:LLY) is one of the Oversold Fundamentally Strong Stocks to Buy Now. On July 30, the company ...

A newly approved Alzheimer’s treatment that can slow progression of the disease won’t be subsidised by the federal government ...

A year after earning FDA approval for Kisunla, Eli Lilly is shining a light on the anti-amyloid Alzheimer’s disease therapy ...

A newly approved Alzheimer’s treatment that can slow progression of the disease won’t be subsidised by the federal government ...

Eli Lilly’s Alzheimer’s disease (AD) drug Kisunla ( donanemab) has demonstrated a growing benefit over three years in ...

Eli Lilly’s Alzheimer’s disease drug Kisunla failed to get the backing of European regulators, who said its benefits don’t outweigh the risk of potentially fatal bleeding in the brain.

Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for ...

Eli Lilly and Company (NYSE: LLY) announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study showing that participants treated with Kisunla (donanemab-azbt) ...

Kisunla (kih-SUHN-lah) is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.

This authorization is specifically for patients who are Apolipoprotein E ε4 (ApoE ε4) heterozygotes or non-carriers. Kisunla, an amyloid-targeting therapy, is now the first of its kind registered in ...

Kisunla reduced cognitive decline by -0.6 at 18 months and then -1.2 at 36 months on the Clinical Dementia Rating Sum of Boxes (CDR-SB) in patients initially treated with Kisunla in the core study ...

INDIANAPOLIS - The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company (NYSE: LLY)'s Kisunla™ (donanemab-azbt) for the treatment of adults with early symptomatic Alzheimer ...